Manjunath (Amit) P. Pai, Pharm.D.
- Clinical and Translation Science Center Scholar, CTSC, School of Medicine, University of New Mexico (2007)
- Clinical Research Scholars Program, General Clinical Research Center, University of New Mexico (2003)
- Fellowship in Infectious Diseases Pharmacotherapy, College of Pharmacy, University Of Illinois at Chicago (2001)
- Pharmacy Practice Residency, Clinical Pharmacology Service, Bassett Healthcare, Cooperstown, New York (1999)
- Doctor of Pharmacy, College of Pharmacy, The University of Texas at Austin & The University of Texas, Health Sciences Center at San Antonio (1998)
HONORS AND AWARDS
- ACPHS Preceptor of the Year (2014)
- ACPHS Researcher of the Year (2014)
- Impact Paper of the Year, Society of Infectious Diseases Pharmacists (2013)
- Regulatory Science Excellence Award, Renal Drug Dosing Group, Center for Drug Evaluation and Research, United States Food and Drug Administration (US FDA), Silver Spring, MD (2011)
- Teacher of the Year, College of Pharmacy, UNM, Albuquerque, NM. (2008)
- Young Investigator Award, Society of Infectious Diseases Pharmacists (2007)
- Drug Therapy Research Award, American Society of Health Systems Pharmacy (2007)
- Pharmacotherapy (Core) - Infectious Diseases and Clinical Pharmacokinetics
- Integrated Problem Solving (Core) - Facilitator
- Advanced Pharmacy Practice Experience (Core) - Preceptor
- Advanced Topics in Infectious Diseases (Elective) - Course Coordinator
Dr. Pai studies strategies to optimize antimicrobial drug dosing in special populations through systems analyses. Dr. Pai’s current work involves the study of the pharmacokinetic and pharmacodynamics of antimicrobials in obese patients. His research area was featured on the nationally syndicated program, Academic Minute, Aired 7/6/2011. WAMC, Northeast Public Radio. An up-to-date profile of Dr. Pai’s work can be accessed through ResearchGate.
Pai MP, Cojutti P, Pea F. Pharmacokinetics and Pharmacodynamics of Continuous Infusion Meropenem in Overweight, Obese, and Morbidly Obese Patients with Stable and Unstable Kidney Function: A Step Toward Dose Optimization for the Treatment of Severe Gram-Negative Bacterial Infections. Clin Pharmacokinet. 2015 Apr 8. [Epub ahead of print]
Zheng H, Truong J, Carroll F, Pai MP. Do formulation differences between the reference listed drug and generic piperacillin-tazobactam impact reconstitution? Antimicrob Agents Chemother. 2015 Mar;59(3):1767-9. doi: 10.1128/AAC.04563-14.
Pai MP, Cojutti P, Pea F. Levofloxacin dosing regimen in severely morbidly obese patients (BMI ≥40 kg/m(2)) should be guided by creatinine clearance estimates based on ideal body weight and optimized by therapeutic drug monitoring. Clin Pharmacokinet. 2014 Aug;53(8):753-62. doi: 10.1007/s40262-014-0154-1.
Pai MP, Neely M, Rodvold KA, Lodise TP. Innovative approaches to optimizing the delivery of vancomycin in individual patients. Adv Drug Deliv Rev. 2014 Nov 20;77:50-7. doi: 10.1016/j.addr.2014.05.016.
Falcone M, Russo A, Venditti M, Novelli A, Pai MP. Considerations for Higher Doses of Daptomycin in Critically Ill Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia. Clin Infect Dis 2013 Sep 17. doi:10.1093/cid/cit582.
Camaione L, Elliott K, Mitchell-Van Steele A, Lomaestro B, Pai MP. Vancomycin Dosing in Children and Young Adults: Back to the Drawing Board. Pharmacotherapy. 2013 Sep 9. doi: 10.1002/phar.1345.
Butterfield JM, Lodise TP, Beegle S, Rosen J, Farkas J, Pai MP. Pharmacokinetics and pharmacodynamics of once-daily administration of intravenous tobramycin in adult patients with cystic fibrosis hospitalized for an acute pulmonary exacerbation. Antimicrob Agents Chemother. 2013 Oct;57(10):5175-7. doi:10.1128/AAC.00539-13.
Pai MP. Serum and urine pharmacokinetics of tigecycline in obese class III and normal weight adults. J Antimicrob Chemother. 2013 Jul 23. [Epub ahead of print]
Butterfield JM, Lodise TP, Beegle S, Rosen J, Farkas J, Pai MP. Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations. J Antimicrob Chemother. 2013 Jul 18. [Epub ahead of print]
Hamilton R, Thai XC, Ameri D, Pai MP. Oral bioavailability of linezolid before and after Roux-en-Y gastric bypass surgery: is dose modification necessary in obese subjects? J Antimicrob Chemother. 2013 Mar;68(3):666-73. doi:10.1093/jac/dks431.
Pai MP, Chen WZ, Garba A, Cui H, Zaffo B, El-Fawal HA, Mousa SA. Effects of obesity and sex on antimicrobial pharmacokinetics and acute kidney injury: validation of a preclinical model. Antimicrob Agents Chemother. 2013 Feb;57(2):716-22. doi: 10.1128/AAC.01194-12.
Pai MP. Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults. Pharmacotherapy. 2012 Sep;32(9):856-68. doi: 10.1002/j.1875-9114.2012.01108.x. (IMPACT PAPER OF THE YEAR, SIDP)
Pai MP, Nafziger AN, Bertino JS Jr. The not so "ideal" body weight-based dosing of Integrilin in obesity. Am Heart J. 2012 Apr;163(4):e23; author reply e25. doi: 10.1016/j.ahj.2012.01.032. Epub 2012 Mar 13. PubMed PMID: 22520549.
Park EJ, Pai MP, Dong T, Zhang J, Ko CW, Lawrence J, Crentsil V, Zhang L, Xu NN. The influence of body size descriptors on the estimation of kidney function in normal weight, overweight, obese, and morbidly obese adults. Ann Pharmacother. 2012 Mar;46(3):317-28. doi: 10.1345/aph.1Q374.
Pai MP, Lodise TP Jr. Oseltamivir and oseltamivir carboxylate pharmacokinetics in obese adults: dose modification for weight is not necessary. Antimicrob Agents Chemother. 2011 Dec;55(12):5640-5. doi: 10.1128/AAC.00422-11.
Pai MP, Nafziger AN, Bertino JS Jr. Simplified estimation of aminoglycoside pharmacokinetics in underweight and obese adult patients. Antimicrob Agents Chemother. 2011 Sep;55(9):4006-11. doi: 10.1128/AAC.00174-11.
Pai MP, Lodise TP. Steady-state plasma pharmacokinetics of oral voriconazole in obese adults. Antimicrob Agents Chemother. 2011 Jun;55(6):2601-5. doi: 10.1128/AAC.01765-10. Epub 2011 Mar 21. PubMed PMID: 21422207;
Pai MP. Estimating the glomerular filtration rate in obese adult patients for drug dosing. Adv Chronic Kidney Dis. 2010 Sep;17(5):e53-62. doi: 10.1053/j.ackd.2010.05.010.
Pai MP, Bruce H, Felton LA. Clinical pharmacokinetics of oral controlled-release 5-fluorocytosine. Antimicrob Agents Chemother. 2010 Mar;54(3):1237-41. doi: 10.1128/AAC.01103-09.
Pai MP, Sakoglu U, Peterson SL, Lyons CR, Sood R. Characterization of BBB permeability in a preclinical model of cryptococcal meningoencephalitis using magnetic resonance imaging. J Cereb Blood Flow Metab. 2009 Mar;29(3):545-53. doi:10.1038/jcbfm.2008.144.
Pai MP, Norenberg JP, Anderson T, Goade DW, Rodvold KA, Telepak RA, Mercier RC. Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin. Antimicrob Agents Chemother. 2007 Aug;51(8):2741-7.
Pai MP, Norenberg JP, Telepak RA, Sidney DS, Yang S. Assessment of effective renal plasma flow, enzymuria, and cytokine release in healthy volunteers receiving a single dose of amphotericin B desoxycholate. Antimicrob Agents Chemother. 2005 Sep;49(9):3784-8.
Pai MP, Rodvold KA, Schreckenberger PC, Gonzales RD, Petrolatti JM, Quinn JP. Risk factors associated with the development of infection with linezolid- and vancomycin-resistant Enterococcus faecium. Clin Infect Dis. 2002 Nov 15;35(10):1269-72.
Pai MP, Paloucek FP. The origin of the "ideal" body weight equations. Ann Pharmacother. 2000 Sep;34(9):1066-9.